Kazia Therapeutics (KZIA) Accumulated Expenses (2016 - 2025)

Kazia Therapeutics has reported Accumulated Expenses for 10 years, with the latest figure at $249768.9 in Q2 2025.

• For the quarter ending Q2 2025, Accumulated Expenses rose 3.84% year-over-year to $249768.9; the trailing twelve-month figure through Jun 2025 stood at $249768.9 (up 3.84% YoY), and the FY2025 full-year result was $249768.9, up 3.84% from the prior year.
• Accumulated Expenses for Q2 2025 stood at $249768.9, up from $240543.9 in the prior quarter.
• The five-year high for Accumulated Expenses was $461168.7 in Q2 2023, with the low at $145402.5 in Q2 2022.
• Historically, Accumulated Expenses has averaged $254645.3 across 5 years, with a median of $240543.9 in 2024.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 217.17% — and 2024, when it plunged 47.84%.
• Kazia Therapeutics' Accumulated Expenses stood at $176342.6 in 2021, then retreated by 17.55% to $145402.5 in 2022, then jumped by 217.17% to $461168.7 in 2023, then sank by 47.84% to $240543.9 in 2024, then advanced by 3.84% to $249768.9 in 2025.
• The last three Accumulated Expenses figures came in at $249768.9 (Q2 2025), $240543.9 (Q2 2024), and $461168.7 (Q2 2023), per Business Quant data.